Royalty Pharma plc - Ordinary Shares - Class A Aktie News

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board, will discuss these updates on January 13, 2026 as part of a webcast presentation to be held at 12:45 p.m. Eastern Time / 9:45 a.m. Pacific Tim...

NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-med...

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company's quarterly dividend over the previous quarter's dividend. The dividend will be paid on March 10, 2026 to shareholders of record at the close...

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront and up to $60 million in sales-based milestones. Evrysdi, marketed by Roche, is an orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatment of spinal m...

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an undisclosed third party for up to $315 million.

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.